Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Leukemia, Mast-Cell 1Leukemia 1

Interventions

fludarabine phosphate 5Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Therapeutics 4Peripheral Blood Stem Cell Transplantation 4Psychiatric Rehabilitation 2Pentetic Acid 2Early Intervention, Educational 2Darbepoetin alfa 2thymoglobulin 1midostaurin 1liposomal doxorubicin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1denileukin diftitox 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thiotepa 1Tacrolimus 1Sulfamethoxazole 1Sucrose 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Mast-Cell × hydrocortisone valerate × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡